Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles matching "skin-cancer"

Clinical trialCLINICALTRIALSYesterday

New Clinical Trial: Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study (NCT01517945)

Researchers at Memorial Sloan Kettering Cancer Center are testing a smartphone app designed to help breast cancer and rare cancer survivors deal with the fear that their cancer might come back. The app uses a technique called Attention and Interpretation Modification (AIM) to help people change how they think about cancer recurrence. The study has enrolled 252 people and is no longer recruiting new participants, but the results could help many cancer survivors in the future.

WHY IT MATTERSThis trial addresses a common but often overlooked mental health challenge for cancer survivors—fear of recurrence—by testing a personalized, accessible mobile app intervention that could be widely available if proven effective.
👁 Watch this spaceBreast CancerRare CancersRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)

Researchers are testing whether combining three cancer drugs—nivolumab, ipilimumab, and cabozantinib—can help treat rare cancers of the bladder, kidney, prostate, and other urinary system organs. This phase 2 trial is actively recruiting 314 patients to see if this drug combination works better than current treatments. The study is being run by the National Cancer Institute.

WHY IT MATTERSThis trial offers patients with rare genitourinary cancers (like collecting duct carcinoma, kidney medullary carcinoma, and rare bladder variants) access to a novel three-drug combination that may be more effective than standard treatments currently available.
You can act on thisBladder AdenocarcinomaBladder Neuroendocrine CarcinomaChromophobe Renal Cell CarcinomaRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases